Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Ave NW
Suite 300E
Washington
DC
20037
United States
Website: http://www.vandapharma.com/
386 articles with Vanda Pharmaceuticals, Inc.
-
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
2/1/2023
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.
-
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
1/6/2023
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.
-
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
12/19/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt ® (iloperidone tablets), a novel atypical antipsychotic, in the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults.
-
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation
12/13/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ® ANDA Litigation.
-
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
12/2/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.
-
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
11/9/2022
Vanda Pharmaceuticals Inc. announced that the company will participate in the following upcoming investor conferences in November 2022.
-
Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
10/26/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes.
-
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
10/21/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera.
-
Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
9/29/2022
Vanda Pharmaceuticals Inc. and OliPass Corporation announced that they have entered into a research and development collaboration agreement to jointly develop a set of antisense oligonucleotide molecules based on OliPass' proprietary modified peptide nucleic acids.
-
Although it was a short week due to the Labor Day holiday, the FDA maintained a steady pace of business.
-
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
9/8/2022
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment Conference in New York City on Wednesday, September 14, 2022.
-
Vanda Pharmaceuticals Announces Notice of Opportunity for an FDA Hearing on the sNDA for Hetlioz® in Jet Lag Disorder
9/7/2022
Vanda Pharmaceuticals Inc. announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application for HETLIOZ® to treat jet lag disorder.
-
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
8/3/2022
"During the second quarter we made significant progress towards commercializing our products and improving access to HETLIOZ® for patients with Non-24," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.
-
Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022
7/27/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.
-
Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference
6/2/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New York City on Thursday, June 9, 2022.
-
Vanda Pharmaceuticals Announces Presentations at SLEEP 2022
5/31/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.
-
Vanda has again taken legal action against the FDA over its supposed failure to grant tradipant Fast Track designation. In its complaint, Vanda is challenging the FDA’s decision to deny the designation.
-
Vanda Pharmaceuticals Announces Presentations at DDW 2022
5/20/2022
Vanda Pharmaceuticals Inc. announced participation at Digestive Disease Week 2022, to be held in San Diego, CA and online from May 21-24, 2022.
-
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
5/5/2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022.
-
Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference
5/4/2022
Vanda Pharmaceuticals Inc. announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022.